P767: CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES

P767: CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES

Bibliographic Details
Main Authors:	H. Yang, G. Garcia-Manero, K. Sasaki, G. Montalban-Bravo, Z. Tang, Y. Wei, T. Kadia, K. Chien, D. Rush, H. Nguyen, A. Kalia, M. Nimmakayalu, C. Bueso-Ramos, H. Kantarjian, L. J. Medeiros, R. Luthra, R. Kanagal-Shamanna
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845952.65942.38

Similar Items

P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME
by: K. Kim, et al.
Published: (2022-06-01)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
by: Samuel Urrutia, et al.
Published: (2023-08-01)

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: K. Chien, et al.
Published: (2022-06-01)

P762: NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS
by: F. Darbaniyan, et al.
Published: (2022-06-01)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: S. Venugopal, et al.
Published: (2022-06-01)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
by: Samuel Urrutia, et al.
Published: (2023-08-01)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
by: S. P. Desikan, et al.
Published: (2022-06-01)

P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION
by: T. Abuasab, et al.
Published: (2022-06-01)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
by: Samuel Urrutia, et al.
Published: (2023-08-01)

P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE
by: K. Kim, et al.
Published: (2022-06-01)

On the strucure of Sovič above Postojna
by: Ladislav Placer
Published: (1995-12-01)

FORMATION OF NANOCRYSTAL STATE IN DETAILS OF CARBON STRUCURAL STEELS
by: A. A. Andrushevich, et al.
Published: (2018-07-01)

RESTRUCTURING OF THE ROMANIAN RAILWAYS; THE IMPACT ON THE FINANCIAL STRUCURE
by: Anduena FÎRTAT
Published: (2008-11-01)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Alex Bataller, et al.
Published: (2023-08-01)

Afro-brazilian fashion sector: Concepts;Strucures and Narrative
by: Patrícia Helena Campestrini Harger
Published: (2016-06-01)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
by: Kelly Chien, et al.
Published: (2023-08-01)

From crystals to pdb: building a high throughput crystallography pipeline for strucural genomics
by: Chiu, H, et al.
Published: (2004)

P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA
by: A. Bazinet, et al.
Published: (2022-06-01)

LA polymorphism in genetic strucure analysis of the aboriginal populations of Northern Russia
by: Evseeva, I, et al.
Published: (2002)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
by: Rashmi Kanagal-Shamanna, et al.
Published: (2021-03-01)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

Neisseria meningitidis serogroup X sequence type 767 in Turkey.
by: Kiliç, A, et al.
Published: (2010)

S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL
by: G. Montalban-Bravo, et al.
Published: (2022-06-01)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
by: Daver, NG, et al.
Published: (2022)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
by: Ian M. Bouligny, et al.
Published: (2025-02-01)

Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
by: Samuel Urrutia, et al.
Published: (2024-11-01)

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER
by: Kelly Chien, et al.
Published: (2023-08-01)

POS-767 BRIDGING THE GAP: DEVELOPING TRANSPLANT PARTNERSHIPS ACROSS BORDERS
by: S. Babloyan, et al.
Published: (2021-04-01)

P767: Genetics of prenatally diagnosed micro/anophthalmia
by: Natalie Burrill, et al.
Published: (2024-01-01)

9.322J / 7.67 Genetic Neurobiology, Fall 2002
by: Quinn, William G., et al.
Published: (2002)

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
by: Juan Jose Rodriguez-Sevilla, et al.
Published: (2024-03-01)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
by: Angela Gil-Perez, et al.
Published: (2019-05-01)

Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms
by: Kelly S. Chien, et al.
Published: (2024-03-01)

Correction to Lancet Glob Health 2015; 3: e767–75
Published: (2016-04-01)

Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation
by: Howard Oster, et al.
Published: (2023-06-01)

Abu Basir al-Asadi (150 AH / 767 AD) Scientific efforts
by: M.M. Ali Najim Abdullah AL-Fayad
Published: (2018-11-01)

Heat Convective Effects on Turbulence and Airflow inside an B767 Aircraft Cabin
by: Maher Shehadi
Published: (2019-09-01)

Obstetrical Disease Spectrum in China: An Epidemiological Study of 111,767 Cases in 2011
by: Xiao-Lin Luo, et al.
Published: (2015-01-01)

Development of an Efficient Transformation System for Halotolerant Yeast Debaryomyces hansenii CBS767
by: Anu Minhas, et al.
Published: (2019-09-01)